ALTEOGEN Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Soon-Jae Park

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	19.7%
Yönetim ortalama görev süresi	2.8yrs
Yönetim Kurulu ortalama görev süresi	Veri yok

Son yönetim güncellemeleri

Güncelleme yok

Recent updates

Is Weakness In ALTEOGEN Inc. (KOSDAQ:196170) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Feb 18

Do Insiders Own Lots Of Shares In ALTEOGEN Inc. (KOSDAQ:196170)?

Dec 27

CEO

Soon-Jae Park

no data

Görev süresi

Dr. Soon-Jae Park, Ph D., serves as the Chief Executive Officer of ALTEOGEN Inc. He has several years of experience in R&D of biomedicine. He served as the Executive Officer at BINEX Co., Ltd.He started w...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Soon-Jae Park	Chief Executive Officer	no data	Veri yok	19.67% ₩ 3.1t
Hang Yeon Kim	CFO & Executive VP	2.8yrs	Veri yok	Veri yok
Sang Woo Kang	Senior Vice President of Management Support Group	2.8yrs	Veri yok	Veri yok
Tae-Yon Chun	Executive VP & Corporate Alliance Officer (CAO)	4.8yrs	Veri yok	Veri yok
Kyuwan Kim	Senior VP & Head of New Drug Development	no data	Veri yok	Veri yok
Vivek B Shenoy	Chief Business Development Officer	2.8yrs	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim: A196170 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

ALTEOGEN Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Recent updates

New major risk - Share price stability

Alteogen Inc. Receives Ministry of Food and Drug Safety (Mfds) Approval for Tergase®

ALTEOGEN's (KOSDAQ:196170) Shareholders Should Assess Earnings With Caution

Full year 2023 earnings released: ₩65.00 loss per share (vs ₩159 loss in FY 2022)

ALTEOGEN (KOSDAQ:196170) Has Debt But No Earnings; Should You Worry?

Now 21% overvalued after recent price rise

Consensus revenue estimates decrease by 13%

Consensus revenue estimates increase by 41%, EPS downgraded

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: ₩148 loss per share (vs ₩122 loss in 3Q 2022)

Price target increased by 23% to ₩83,333

Consensus revenue estimates fall by 24%

Alteogen Inc. Announces Clinical Trial of Tergase Showed Zero Incidence of ADA

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to ₩62,667

Consensus forecasts updated

Price target decreased to ₩70,000

Consensus forecasts updated

Price target decreased to ₩79,000

Price target decreased to ₩106,000

Forecast breakeven date pushed back to 2022

Price target increased to ₩142,000

ALTEOGEN Inc.'s (KOSDAQ:196170) Has Found A Path To Profitability

Alteogen Inc. Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients

New 90-day low: ₩132,700

Is Weakness In ALTEOGEN Inc. (KOSDAQ:196170) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

New 90-day low: ₩143,700

ALTEOGEN Inc. announced that it has received KRW 74.999925 billion in funding from SG Core Co., Ltd.

Do Insiders Own Lots Of Shares In ALTEOGEN Inc. (KOSDAQ:196170)?

Analysts update estimates

ALTEOGEN Inc. announced that it expects to receive KRW 29.9992875 billion in funding from Shinhan Bank, SL Investment, Future Growth Strategy Bio New Technology Investment Fund, Korea Investment Holdings Co., Ltd., Korea Securities Finance Corporation

New 90-day low: ₩155,700

New 90-day high - ₩209,000

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi